Diminished neurokinin-1 receptor availability in patients with two forms of chronic visceral pain - PubMed (original) (raw)
Comparative Study
. 2013 Jul;154(7):987-96.
doi: 10.1016/j.pain.2013.02.026. Epub 2013 Mar 5.
Natasha A Feier, Alberto Bert, Jennifer A Labus, Maunoo Lee, Jean Stains, Bahar Ebrat, Stephanie M Groman, Kirsten Tillisch, Arthur L Brody, Edythe D London, Mark A Mandelkern, Emeran A Mayer
Affiliations
- PMID: 23582152
- PMCID: PMC4294187
- DOI: 10.1016/j.pain.2013.02.026
Comparative Study
Diminished neurokinin-1 receptor availability in patients with two forms of chronic visceral pain
Johanna M Jarcho et al. Pain. 2013 Jul.
Abstract
Central sensitization and dysregulation of peripheral substance P and neurokinin-1 receptor (NK-1R) signaling are associated with chronic abdominal pain in inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). Although positron emission tomography (PET) has demonstrated that patients with injury-related chronic pain have diminished NK-1R availability in the brain, it is unknown whether these deficits are present in IBD and IBS patients, who have etiologically distinct forms of non-injury-related chronic pain. This study's aim was to determine if patients with IBD or IBS exhibit deficits in brain expression of NK-1Rs relative to healthy controls (HCs), the extent to which expression patterns differ across patient populations, and if these patterns differentially relate to clinical parameters. PET with [(18)F]SPA-RQ was used to measure NK-1R availability by quantifying binding potential (BP) in the 3 groups. Exploratory correlation analyses were performed to detect associations between NK-1R BP and physical symptoms. Compared to HCs, IBD patients had NK-1R BP deficits across a widespread network of cortical and subcortical regions. IBS patients had similar, but less pronounced deficits. BP in a subset of these regions was robustly related to discrete clinical parameters in each patient population. Widespread deficits in NK-1R BP occur in IBD and, to a lesser extent, IBS; however, discrete clinical parameters relate to NK-1R BP in each patient population. This suggests that potential pharmacological interventions that target NK-1R signaling may be most effective for treating distinct symptoms in IBD and IBS.
Copyright © 2013 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Conflict of interest statement: The authors report no conflict of interest.
Figures
Fig. 1
Average whole-brain neurokinin-1 receptor binding potential across all participants.
Fig. 2
Whole-brain voxel-wise statistical parametric mapping analysis depicting regions with lower levels of neurokinin-1 receptor binding in inflammatory bowel disease (IBD) (A) and irritable bowel syndrome (IBS) patients (B), relative to healthy controls (voxel extent threshold P < 0.001; cluster extent threshold > 20).
Comment in
- New pieces for the substance P puzzle.
Linnman C. Linnman C. Pain. 2013 Jul;154(7):966-967. doi: 10.1016/j.pain.2013.04.020. Epub 2013 Apr 12. Pain. 2013. PMID: 23643331 No abstract available.
Similar articles
- New pieces for the substance P puzzle.
Linnman C. Linnman C. Pain. 2013 Jul;154(7):966-967. doi: 10.1016/j.pain.2013.04.020. Epub 2013 Apr 12. Pain. 2013. PMID: 23643331 No abstract available. - Neurokinin-1-receptor antagonism decreases anxiety and emotional arousal circuit response to noxious visceral distension in women with irritable bowel syndrome: a pilot study.
Tillisch K, Labus J, Nam B, Bueller J, Smith S, Suyenobu B, Siffert J, McKelvy J, Naliboff B, Mayer E. Tillisch K, et al. Aliment Pharmacol Ther. 2012 Feb;35(3):360-7. doi: 10.1111/j.1365-2036.2011.04958.x. Aliment Pharmacol Ther. 2012. PMID: 22221140 Free PMC article. Clinical Trial. - Neurokinin-1 receptor expression in inflammatory bowel disease: molecular quantitation and localisation.
Goode T, O'Connell J, Anton P, Wong H, Reeve J, O'Sullivan GC, Collins JK, Shanahan F. Goode T, et al. Gut. 2000 Sep;47(3):387-96. doi: 10.1136/gut.47.3.387. Gut. 2000. PMID: 10940277 Free PMC article. - Role of corticotropin-releasing hormone in irritable bowel syndrome and intestinal inflammation.
Fukudo S. Fukudo S. J Gastroenterol. 2007 Jan;42 Suppl 17:48-51. doi: 10.1007/s00535-006-1942-7. J Gastroenterol. 2007. PMID: 17238026 Review. - Pruritogenic mechanisms and gut sensation: putting the "irritant" into irritable bowel syndrome.
Brizuela M, Castro J, Harrington AM, Brierley SM. Brizuela M, et al. Am J Physiol Gastrointest Liver Physiol. 2021 Jun 1;320(6):G1131-G1141. doi: 10.1152/ajpgi.00331.2020. Epub 2021 May 5. Am J Physiol Gastrointest Liver Physiol. 2021. PMID: 33949199 Review.
Cited by
- Long-term upregulation of cortical glutamatergic AMPA receptors in a mouse model of chronic visceral pain.
Liu SB, Zhang MM, Cheng LF, Shi J, Lu JS, Zhuo M. Liu SB, et al. Mol Brain. 2015 Nov 19;8(1):76. doi: 10.1186/s13041-015-0169-z. Mol Brain. 2015. PMID: 26585043 Free PMC article. - A lipid-anchored neurokinin 1 receptor antagonist prolongs pain relief by a three-pronged mechanism of action targeting the receptor at the plasma membrane and in endosomes.
Mai QN, Shenoy P, Quach T, Retamal JS, Gondin AB, Yeatman HR, Aurelio L, Conner JW, Poole DP, Canals M, Nowell CJ, Graham B, Davis TP, Briddon SJ, Hill SJ, Porter CJH, Bunnett NW, Halls ML, Veldhuis NA. Mai QN, et al. J Biol Chem. 2021 Jan-Jun;296:100345. doi: 10.1016/j.jbc.2021.100345. Epub 2021 Jan 28. J Biol Chem. 2021. PMID: 33515548 Free PMC article. - Honokiol for the Treatment of Neonatal Pain and Prevention of Consequent Neurobehavioral Disorders.
Woodbury A, Yu SP, Chen D, Gu X, Lee JH, Zhang J, Espinera A, García PS, Wei L. Woodbury A, et al. J Nat Prod. 2015 Nov 25;78(11):2531-6. doi: 10.1021/acs.jnatprod.5b00225. Epub 2015 Nov 5. J Nat Prod. 2015. PMID: 26539813 Free PMC article. - Supraspinal Mechanisms of Intestinal Hypersensitivity.
Lyubashina OA, Sivachenko IB, Panteleev SS. Lyubashina OA, et al. Cell Mol Neurobiol. 2022 Mar;42(2):389-417. doi: 10.1007/s10571-020-00967-3. Epub 2020 Oct 8. Cell Mol Neurobiol. 2022. PMID: 33030712 Review. - Role of brain imaging in disorders of brain-gut interaction: a Rome Working Team Report.
Mayer EA, Labus J, Aziz Q, Tracey I, Kilpatrick L, Elsenbruch S, Schweinhardt P, Van Oudenhove L, Borsook D. Mayer EA, et al. Gut. 2019 Sep;68(9):1701-1715. doi: 10.1136/gutjnl-2019-318308. Epub 2019 Jun 7. Gut. 2019. PMID: 31175206 Free PMC article. Review.
References
- Abbadie C, Brown JL, Mantyh PW, Basbaum AI. Spinal cord substance P receptor immunoreactivity increases in both inflammatory and nerve injury models of persistent pain. Neuroscience. 1996;70:201–9. - PubMed
- Alpar EK, Onuoha G, Killampalli VV, Waters R. Management of chronic pain in whiplash injury. J Bone Joint Surg Br. 2002;84:807–11. - PubMed
- Apkarian AV, Bushnell MC, Treede RD, Zubieta JK. Human brain mechanisms of pain perception and regulation in health and disease. Eur J Pain. 2005;9:463–84. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- T32 MH017140/MH/NIMH NIH HHS/United States
- F31 DA021951/DA/NIDA NIH HHS/United States
- F31 DA028812/DA/NIDA NIH HHS/United States
- R24 AT002681/AT/NCCIH NIH HHS/United States
- T32-MH017140/MH/NIMH NIH HHS/United States
- F31-DA021951/DA/NIDA NIH HHS/United States
- AT00268/AT/NCCIH NIH HHS/United States
- R01 DA020872/DA/NIDA NIH HHS/United States
- I01 CX000412/CX/CSRD VA/United States
- R01 DA20872/DA/NIDA NIH HHS/United States
- F313 DA028812/DA/NIDA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources